Latest news headline


MVX-ONCO Explained



Geneva University Hospitals (HUG), the University of Geneva (UNIGE), the Infectious Disease Research Centre at Laval University in Quebec (Canada) and MaxiVAX – a Geneva-based company specialising in biotechnology – are working together to develop a SARS-CoV-2 vaccine. This joint research programme aims to create a vaccine combining an immunostimulator and a specific coronavirus target, namely the spike surface protein. This is administered by intradermal injection with the immunostimulator, whose role is to produce an adjuvant capable of stimulating the immune system. It is implanted under the skin via cell encapsulation, a technology that is already undergoing Phase II clinical tests led by HUG in collaboration with MaxiVAX in the area of cancer immunotherapy.
The first pre-clinical tests for perfecting the vaccine will be carried out on mice in the coming weeks. If preliminary tests prove encouraging, a clinical trial could be set up in the near future.


MaxiVAX awarded €2,785,000 European Commission grant and announces successful closing of its Series B 2 round for an amount of CHF 5 million

  • MaxiVAX wins grant among 94 projects funded out of 2,015 applications
  • Closing of Series B 2 round of CHF 5 million from new and existing investors
  • Funds used for Phase 2 cancer programs

MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.

The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194